Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer

por Nukatsuka, Mamoru, Fujioka, Akio, Nagase, Hideki, Tanaka, Gotaro, Hayashi, Hiroaki
Publicado 2023

Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model

por Tsunekuni, Kenta, Kawakami, Hisato, Matsuoka, Kazuaki, Nagase, Hideki, Mitani, Seiichiro, Nakagawa, Kazuhiko
Publicado 2020

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728

por Irie, Hiroki, Kawabata, Rumi, Fujioka, Yayoi, Nakagawa, Fumio, Itadani, Hiraku, Nagase, Hideki, Ito, Kimihiro, Uchida, Junji, Ohkubo, Shuichi, Matsuo, Kenichi
Publicado 2020

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

por TANAKA, NOZOMU, SAKAMOTO, KAZUKI, OKABE, HIROYUKI, FUJIOKA, AKIO, YAMAMURA, KEISUKE, NAKAGAWA, FUMIO, NAGASE, HIDEKI, YOKOGAWA, TATSUSHI, OGUCHI, KEI, ISHIDA, KEIJI, OSADA, AKIKO, KAZUNO, HIROMI, YAMADA, YUKARI, MATSUO, KENICHI
Publicado 2014